Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$276.80 USD

276.80
512,554

-7.80 (-2.74%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $276.78 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

Can Cigna's (CI) Q1 Earnings Beat on Medical Customers Growth?

by Zacks Equity Research

The first-quarter results of Cigna (CI) are likely to reflect an expanding customer base and growth in specialty pharmacy services.

Zacks Equity Research

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.

Zacks Equity Research

Embecta (EMBC) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.

Zacks Equity Research

Charles River (CRL) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.

Zacks Equity Research

Are Medical Stocks Lagging BioRad Laboratories (BIO) This Year?

by Zacks Equity Research

Here is how Bio-Rad Laboratories (BIO) and GSK (GSK) have performed compared to their sector so far this year.

Zacks Equity Research

Alcon (ALC) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Amid persistent supply-chain headwinds, Alcon's (ALC) first-quarter top-line results are likely to reflect the commercial execution of new product launches across its segments and contributions from strategic alliances.

Zacks Equity Research

What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.

John Blank headshot

What to do with the Real Estate sector?

by John Blank

Shorts have been pounding away. Where to from here?

Zacks Equity Research

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Quest Diagnostics (DGX) base business registers growth in the first quarter of 2023.

Zacks Equity Research

Integra's (IART) Q1 Earnings Match Estimates, Margins Contract

by Zacks Equity Research

In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.

Zacks Equity Research

Bio-Rad Laboratories (BIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Bio-Rad (BIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Edwards Lifesciences (EW) Q1 Earnings Top Estimates, '23 View Up

by Zacks Equity Research

Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL Precision system in Europe.

Zacks Equity Research

Lamb Weston and TTEC Holdings have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Lamb Weston and TTEC Holdings have been highlighted as Zacks Bull and Bear of the Day.

Zacks Equity Research

The Zacks Analyst Blog Highlights BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp

by Zacks Equity Research

BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp are included in this Analyst Blog.

Zacks Equity Research

CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

CVS Health's (CVS) digital capabilities are expected to have driven consumer engagement across all CVS Health businesses in Q1.

Zacks Equity Research

Boston Scientific (BSX) Q1 Earnings Beat, 2023 View Raised

by Zacks Equity Research

Reported and organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in the reported quarter.

Zacks Equity Research

Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

The year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments drove Thermo Fisher's (TMO) Q1 revenues.

Zacks Equity Research

AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal 2023 second-quarter results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.

Urmimala Biswas headshot

3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings

by Urmimala Biswas

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.

Zacks Equity Research

LabCorp (LH) Q1 Earnings Miss Estimates, Margins Decline

by Zacks Equity Research

The decline in COVID-19 PCR and antibody testing sales, the severe foreign exchange headwind and inflationary pressure hurt LabCorp's (LH) business performance in Q1.

Zacks Equity Research

Stryker (SYK) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) first-quarter results are expected to reflect strong segmental performances. However, rising costs are likely to have continued hurting margins.

Zacks Equity Research

Bio-Rad Laboratories (BIO) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Bio-Rad Laboratories (BIO) closed the most recent trading day at $461.80, moving -1.17% from the previous trading session.

Zacks Equity Research

Will Humana's (HUM) Q1 Earnings Beat on Insurance Unit Strength?

by Zacks Equity Research

Humana's (HUM) first-quarter results are likely to reflect surging premiums and investment income.

Zacks Equity Research

Can Rising Expenses Hurt Teladoc Health's (TDOC) Q1 Earnings?

by Zacks Equity Research

Teladoc Health's (TDOC) first-quarter results are likely to reflect growth in Access Fees revenues and total visits.

Zacks Equity Research

GYN Surgical Sales to Aid Hologic (HOLX) in Q2 Earnings

by Zacks Equity Research

Strong performance led by MyoSure and NovaSure is expected to have driven Hologic' s (HOLX) Q2 performance.